Viridis Mining (ASX: VMM) Signs Estimated US$915 Million Rare Earths Deal. Can It Turn Demand Into Profits?

A binding rare earths offtake agreement representing an estimated US$915 million in minimum revenue has strengthened the commercial outlook for Viridis Mining and Minerals Limited (ASX: VMM). The agreement with European chemicals group Solvay provides substantial future sales commitments for its Colossus Rare Earth Project in Brazil.

However, with significant project financing still required, the bigger question is whether Viridis can turn contracted demand into profitable production.

Key Numbers

• US$915 million: Estimated minimum revenue from contracted magnetic rare earth volumes between 2029 and 2034, subject to delivery.
• 70%: Approximate proportion of forecast mixed rare earth carbonate production covered by minimum offtake volumes.
• 64%: Approximate proportion of forecast magnetic rare earth production covered by the agreement.
• US$1.196 billion: Estimated after-tax net present value of Colossus under its definitive feasibility study, using an 8% discount rate.
• A$119.7 million: Cash held at 30 September 2026.

The Latest Development: Solvay Secures Future Rare Earths Supply

On 5 November 2026, Viridis confirmed a binding long-term offtake agreement with Rhodia Operations SAS, part of Solvay, covering production from its Colossus project in Minas Gerais, Brazil.

The agreement includes seven payable rare earth elements, notably neodymium, praseodymium, dysprosium and terbium, which are essential for high-performance permanent magnets used in electric vehicles, renewable energy infrastructure and industrial applications.

The initial agreement extends from targeted first production in 2028 until 31 December 2034.

Binding take-or-pay commitments commence on the earlier of commercial operations or 1 January 2029.

The estimated US$915 million revenue figure is based on contractual price floors for four magnetic rare earth elements, adjusted for payability.

Importantly, this is not revenue already earned or cash received. Viridis must successfully construct Colossus, commence production and deliver contracted volumes to realise the commercial benefits.

What Stands Out: Strong Project Economics, but Funding Remains Critical

The Solvay agreement strengthens Colossus' commercial position by securing substantial demand before construction is completed.

Viridis' August 2026 definitive feasibility study outlined a processing operation targeting five million tonnes annually, supported by ore reserves and a 25-year production target.

The study estimated an after-tax internal rate of return of 36.4%, with a capital payback period of 2.7 years.

Initial development capital was estimated at US$449 million, including US$44 million in contingency.

These projections suggest attractive potential economics, although they depend on commodity prices, operating costs and successful project delivery.

Colossus also benefits from ionic adsorption clay mineralisation, which may offer processing advantages compared with certain hard-rock rare earth deposits.

However, financing remains a significant hurdle.

Viridis has secured up to US$120 million in strategic equity funding commitments and approval for a R$77.5 million Brazilian development bank facility.

The company has also previously identified approximately US$280 million in remaining senior debt requirements.

While the Solvay agreement could strengthen lender confidence, funding commitments should not be confused with fully received capital.

What the Company Is Doing Now

Viridis is progressing Colossus from feasibility towards construction readiness.

The company has appointed Sedgman and Blossom as engineering, procurement and construction management partners and placed orders for critical long-lead equipment.

It has also supplied demonstration plant material to Solvay's French processing facility for product qualification.

A separate licensing and technical services arrangement with Solvay remains under consideration.

These activities could support the targeted 2028 production timetable, although financing, regulatory approvals and construction execution remain essential.

Insight: Does the US$915 Million Agreement Strengthen Viridis' Valuation Case?

We think the Solvay agreement materially improves Colossus' commercial credibility by securing substantial future demand and providing contractual price protection. However, the project's estimated US$1.196 billion after-tax net present value is a feasibility-stage calculation, not a guaranteed market valuation. Significant financing requirements, construction costs and execution risks remain. Viridis has strengthened its case for developing a commercially competitive rare earths operation, but we believe completing the funding package and demonstrating reliable project delivery will matter more than the headline value of its offtake commitments.

What Happens Next?

The immediate priority is securing the remaining project financing and progressing towards a final investment decision.

Shareholders should monitor financing agreements, regulatory approvals, construction expenditure and progress towards targeted first production in 2028.

The Solvay agreement provides Viridis with a stronger commercial foundation, but the decisive milestone will be converting contracted demand into reliable production and sustainable operating cash flow.

For now, Colossus has demonstrated meaningful commercial potential. Whether that potential translates into lasting shareholder value will depend on disciplined funding, construction and operational execution.